Surgical Treatment of Renal Cell Cancer Liver Metastases: A Population-Based Study

Ruys, Anthony T.; Tanis, Pieter J.; Nagtegaal, Irıs D.; Duijvendijk, Peter van; Verhoef, Cornelis; Porte, Robert J.; Gulik, Thomas M. van

doi:10.1245/s10434-010-1526-x

Cited by 63 publications

(61 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, these results compare favorably to those of hepatic resection for hepatic metastases 13. Our series of patients adds to this limited data set and will hopefully lead to hypothesis generation in order to formulate further trials.…”

Section: Discussionmentioning

confidence: 58%

Liver Directed Therapy for Renal Cell Carcinoma

Langan¹,

Ripley²,

Davis³

et al. 2012

J. Cancer

View full text Add to dashboard Cite

Background: Metastatic renal cell carcinoma (RCC) to the liver portrays a poor prognosis and liver directed therapy remains controversial. We aimed to determine potential selection criteria for patients who might benefit from this strategy.Materials and Methods: We evaluated 247 consecutive patients with RCC metastatic to the liver from a prospectively maintained database.Results: Eighteen patients received liver directed therapy (18/247, 7%). Ten patients underwent liver resection (10/247, 4%) and eight patients underwent radiofrequency ablation (RFA, 8/247, 3%). All were rendered free of disease in the liver. Five had synchronous liver disease and underwent synchronous resections with their primary. Mortality was 0%. Fourteen had single (surgery 7, RFA 7) and four (surgery 3, RFA 1) had multiple liver lesions, respectively. Median size of lesions was 5cm (0.5 - 10cm) and 2.5cm (1 - 6cm) in the surgery and RFA groups, respectively. Median DFI was 10 months, and no difference was observed in those with a longer vs. shorter than median DFI (p = 0.95); liver specific progression free survival for the surgery and RFA groups were 4 and 6 months, respectively (p= 0.93). 1, 3 and 5-year actuarial survivals for the whole group were 89%, 40%, 27%. Median survival for the surgery group was 24 (3 to 254+) months, and for the RFA group 15.6 (7-56+) months (p = 0.56). Metachronous liver disease was associated with prolonged survival (p = 0.02).Conclusions: Liver directed therapy for RCC is safe. For highly selected patients with metachronous liver RCC metastases, liver directed therapy should be considered in a multidisciplinary manner.

show abstract

Section: Discussionmentioning

confidence: 58%

Liver Directed Therapy for Renal Cell Carcinoma

Langan¹,

Ripley²,

Davis³

et al. 2012

J. Cancer

View full text Add to dashboard Cite

show abstract

“…In addition, liver surgery is accepted as a treatment option in patients with neuroendocrine liver metastases (NELM), with 5-year survival ranging from 60 to 80% [4,5,6]. Selected patients with non-CRLM, non-NELM may also be potential candidates for surgical treatment, since several studies demonstrated an association with improved survival after liver resection [7,8,9,10,11,12]. …”

Section: Introductionmentioning

confidence: 99%

“…A similar French study reported an increase in liver resection from 2 to 20% in the period between 1976 and 2000 [22]. In both studies, only patients with liver metastases from colorectal origin were evaluated, and only few nationwide studies are available on liver resections performed for non-CRLM [8,10,12]. …”

Section: Introductionmentioning

confidence: 99%

Liver Resection for Metastatic Disease; A Population-Based Analysis of Trends

Ridder

Lemmens²,

Overbeek³

et al. 2016

Dig Surg

View full text Add to dashboard Cite

Objective: The study aims to evaluate all patients who underwent liver resection for metastatic disease for demographics, characteristics of the primary tumor and metastasis, volume of liver resection specimens per pathology laboratory and to describe trends in surgical treatment. Methods: Data were prospectively collected using the Dutch nationwide pathology network. All pathology reports containing details on liver resections for metastatic disease between January 2001 and December 2010 were evaluated. Results: A total of 3,916 liver resections were performed in 3,699 patients with a median age of 63 years (range 1-91). The primary tumor was mainly colorectal (n = 3,256; 88.0%). The number of ‘high volume liver centers' increased from 2 to 12 in the study period, whereas the number of ‘low volume centers' decreased. The number of liver resections increased from 224 to 596 per year (p ≤ 0.0001). A significant increase was demonstrated in elderly patients, patients with multiple metastases, liver resections for smaller metastases and minor liver resections. Conclusion: Although the majority of patients were young and had solitary metastasis, indications for liver resection are expanding as indicated by increasing numbers of elderly and patients with multiple liver metastases. Patients with non-colorectal liver metastases were seldom candidates for resection.

show abstract

“…There has been an increase in the incidence of RCC in recent years. More than one-third of patients with RCC have evidence of metastases at the time of diagnosis, and approximately 33% develop systemic recurrence after primary tumor resection [4,5]. The lung is the most common site of distant recurrence.…”

Section: Introductionmentioning

confidence: 99%